Martin Zimmermann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Martin Zimmermann has a total of 241 co-authors. Here are the top co-authors by number of shared publications:
- Martin Schrappe
University Medical Center Schleswig-Holstein, Kiel, Germany
90 shared publications - Andishe Attarbaschi
St. Anna Children's Hospital, Vienna, Austria
77 shared publications - Sarah Elitzur
Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA, United States
76 shared publications - Barbara Buldini
Pediatric Hematology, Oncology, and Stem Cell Transplant Division, Maternal and Child Health Department, Padua University, Padua, Italy
75 shared publications - Franco Locatelli
Department of Pediatric Hematology/Oncology, Cell and Gene Therapy IRCCS Bambino Gesù Children's Hospital Rome Italy
75 shared publications - Jan Stary
Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
75 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by Wiley in HemaSphere
- Vol. 10 (9)
Identification of favorable subgroups of pediatric high‐hyperdiploid acute lymphoblastic leukemia—A retrospective multinational study
- 17 September 2026
- Published by Wiley in HemaSphere
- Vol. 10 (9)
Open AccessIdentification of favorable subgroups of pediatric high‐hyperdiploid acute lymphoblastic leukemia—A retrospective multinational study
- Open Access
- 16 July 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (4)
Excess body weight at diagnosis is associated with inferior ALL outcomes in male adolescents in the ALL-BFM 2000 study
- 16 July 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (4)
Open AccessExcess body weight at diagnosis is associated with inferior ALL outcomes in male adolescents in the ALL-BFM 2000 study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
A multi-national consortium of γδ T-ALL study.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
A multi-national consortium of γδ T-ALL study.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S16 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
Differentially expressed genes (adjusted P <0.01 ) between PF382-STAG2KO and PF382-WT.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S16 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
Differentially expressed genes (adjusted P <0.01 ) between PF382-STAG2KO and PF382-WT.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
Comparison of clinical characteristics and outcomes between gamma delta T-ALL and non-gamma delta T-ALL.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
Comparison of clinical characteristics and outcomes between gamma delta T-ALL and non-gamma delta T-ALL.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
The genomic features of “Chromosome gains” and “TLX3” subtypes.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
The genomic features of “Chromosome gains” and “TLX3” subtypes.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
The gene expression profiles of γδ T-ALL.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
The gene expression profiles of γδ T-ALL.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S21 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
Compounds used in single-dose (10uM) drug screening.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S21 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
Compounds used in single-dose (10uM) drug screening.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S12 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
Differentially expressed genes (adjusted P <0.01 ) in STAG2/LMO2 subtype compared to other T-ALL cases.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S12 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
Differentially expressed genes (adjusted P <0.01 ) in STAG2/LMO2 subtype compared to other T-ALL cases.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S19 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
Differential peaks of H3K27ac and differentially expressed genes in gene-edited PF382 model.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S19 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
Differential peaks of H3K27ac and differentially expressed genes in gene-edited PF382 model.